Article successfully added.

CyFlow™ CD25 Biotin

CyFlow™ CD25 Biotin
Alternative Name: IL2Rα , p55, TAC
Antibody: Yes
Antigen: CD25
Application: Flow cytometry
Clonality: monoclonal
Clone: MEM-181
Field of Interest: Immunophenotyping
Format/Fluorochrome: Biotin
Isotype: IgG1
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: AT267296

For Research Use Only

HLDA Workshop HLDA VI—WS Code NL N-L024 Concentration Unit mg/mL Concentration 1... more
CyFlow™ CD25 Biotin
HLDA WorkshopHLDA VI—WS Code NL N-L024
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
Volume0.1 mL
ImmunogenPHA-activated peripheral blood leucocytes
Background InformationCD25 (IL2Rα, Tac) is a ligand-binding α subunit of interleukin 2 receptor (IL2R). Together with β and γ subunit CD25 constitues the high affinity IL2R, whereas CD25 alone serves as the low affinity IL2R. CD25 expression rapidly increases upon T cell activation. The 55 kDa CD25 molecule is enzymatically cleaved and shed from the cell surface as a soluble 45 kDa s-Tac, whose concentration in serum can be used as a marker of T cell activation. Expression of CD25 indicates the neoplastic phenotype of mast cells. Humanized anti CD25 antibodies represent a useful tool to reduce the incidence of allograft rejection as well as the severity of graft versus host reaction, and radioimmunoconjugates of anti-CD25 antibodies can be used against CD25 expressing lymphomas.
UsageThe reagent is designed for indirect immunofluorescence analysis by Flow Cytometry. Suggested working usage is 2·µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Lai KN, Leung JC, Lai FM: Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T‑lymphocytes in vitro. Pathology. 1991 Jul; 23(3):224‑8. < PMID: 1838146 > | Scheibenbogen C, Keilholz U, Richter M, Andreesen R, Hunstein W: The interleukin‑2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75). Res Immunol. 1992 Jan; 143(1):33‑7. < PMID: 1565844 > | Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland Publishing Inc, New York. 1997; 1‑1342. < NLM ID: 9712219 > | Morris JC, Waldmann TA: Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis. 2000 Nov; 59(Suppl 1):i109‑14. < PMID: 11053100 > | Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004 Oct; 28(10):1319‑25. < PMID: 15371947 > | Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single‑molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int Immunol. 2007 May; 19(5):675‑84. < PMID: 17446208 >